← SynDRA
PRIMAQUINE
SynDRA canonical compound SYN0000549 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | antimalarial agent | DNA inhibitor |
|---|
| Indication | malaria |
|---|
| Disease area | infectious disease |
|---|
All known targets
- AHR
- CRT
- CYP1A2
- G6PD
- HBA1
- HSP90AA1
- KCNH2
- MAOA
- MAOB
- NQO2
- SHMT2
- SLC6A4
Mechanisms of action (all sources)
- DNA inhibitor
- antimalarial agent, dna inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NSD1
- ESR1
- PDE3A
- PTGS1
- DRD3
- HTR1A
- CHRM2
- TST
- HRH1
- MAPK1
- NR1I2
- NPY2R
- NPY1R
- MMP9
- MMP1
- HDAC6
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- LCK
- HRH2
- KDR
- NR3C1
- KDM4A
- IDH1
- HMBS
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HMGCR
- HRH3
- KDM4E
- ABCB11
- GHSR
- SENP8
- USP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- APAF
- NF2L2
- NTM1A
- NTMT1
- PADI4
- PAX8
- PPBI
- PPCEL
- PPP1CA
- PSIP1
- SENP6
- SENP7
- SYK
- TACC3
- THB
- TP53
- TYDP2
- NSD2
- MLLT3
- ARNT
- MCL1
- ATXN2
- B2CL1
- CASP3
- CP1A2
- CP2C9
- CP2CJ
- CP2D6
- CP3A4
- CP3A7
- ESRRA
- GSTO1
- IDHC
- KCMA1
- KCMB2
- KSYK
- UBP1
Drug classes
- Antimalarial
- Anti-Infective Agents
- Antimalarials
- Antiparasitic Agents
- Antiprotozoal Agents
- antimalarial agent
ATC classes
Cross-references
Synonyms
- ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
- PRIMAQUINE PHOSPHATE
- primachin
- primaquin
- dl-Primaquine
- (+/-)-Primaquine
- primaquine phosphate
- primaquine diphosphate
- Primaquina
- Kanaprim
- Maliride
- Neo-quipenyl
- Primachin
- NSC-27296
- SN-13272
- WR 2975
- Primachina
- Primachinum
- Primaquin
- Primaquinum
- Primachina [DCIT]
- SN 13272
- Dl-Primaquine
- Kanaprim (TN)
- Neo-Quipenyl
- Primaquina [INN-Spanish]
- Primaquine (INN)
- Primaquine Bis-Phosphoric Acid
- Primaquine [INN:BAN]
- Primaquinum [INN-Latin]
- SN 13,272
- TG1-296
- TG1-297
- Ethylbutylamino)-6-methoxyquinoline
- S. N. 13272
- N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine
- (+)-Primaquine
Reported adverse events
- Dizziness
- Nausea
- Rash
- Leukopenia
Look up PRIMAQUINE in the interactive SynDRA portal →